News Search Results
Aug 14, 2026, 16:30 ET Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
cancer; and,Phase 1 data for LYMPHIR administered prior to CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL) presented at 2026 ASTCT® & CIBMTR® Tandem Meetings, demonstrating:86% ORR, including 57% complete
More news about: Citius Oncology, Inc.
Aug 14, 2026, 16:30 ET Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
including 57% complete response, with no dose-limiting toxicities observed. These positive signals point to LYMPHIR's potential beyond cutaneous T-cell lymphoma. As we scale, we remain focused on disciplined execution and building the long-term sustainable value of LYMPHIR," concluded Mazur.Fiscal
More news about: Citius Pharmaceuticals, Inc.
Aug 13, 2026, 16:10 ET VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
announced the submission for peer review of a clinical manuscript reporting the high accuracy of our Nu.Q® Vet feline prototype assay in detecting lymphoma in cats, our third species. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone
More news about: VolitionRx Limited
Aug 13, 2026, 08:00 ET Curis, Inc. Announces Pricing of $5.6 Million Public Offering
inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of
More news about: Curis, Inc.
Aug 13, 2026, 07:30 ET ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily
More news about: ADC Therapeutics SA
Aug 12, 2026, 10:31 ET CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Grow Significantly at a CAGR of 6.8% During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Pipeline | DelveInsight
pivotal T-RRex trial evaluating WU-CART-007 in patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).The anticipated launch of these emerging therapies are poised to transform the CAR T-cell therapy for ALL market landscape in the coming
More news about: DelveInsight Business Research, LLP
Aug 12, 2026, 10:01 ET Cancer Tumor Profiling Market worth $19.87 billion by 2031 - Exclusive Report by MarketsandMarkets™
275 million upfront and up to USD 175 million in earnouts. The transaction adds phased-variant ctDNA technology and expands Natera's MRD position in lymphoma and solid tumors.August 2025
More news about: MarketsandMarkets
Aug 12, 2026, 08:00 ET Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
at such a pivotal stage in the Company's growth," said Dr. Peri. "Citius Oncology is addressing a serious and underserved need in cutaneous T-cell lymphoma, and I look forward to contributing to the Board's strategic oversight as the Company advances its mission of bringing innovative, targeted oncology
More news about: Citius Oncology, Inc.
Aug 10, 2026, 02:36 ET Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated
More news about: Swedish Orphan Biovitrum AB
Aug 10, 2026, 02:32 ET Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated
More news about: Swedish Orphan Biovitrum AB
Aug 07, 2026, 07:30 ET Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results
developing HyBryte™ (SGX301 or synthetic hypericin sodium), a photodynamic therapy utilizing visible light, for the treatment of cutaneous T-cell lymphoma (CTCL) in a Phase 3 study called "FLASH2" (Fluorescent Light Activated Synthetic Hypericin 2). The Data Monitoring Committee completed its interim
More news about: SOLIGENIX, INC.
Aug 06, 2026, 07:30 ET ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.Headquartered
More news about: ADC Therapeutics SA
Aug 05, 2026, 09:17 ET Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
over quarterLYMPHIR's near-universal payer coverage expands market accessInitial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds $400 millionCRANFORD, N.J., Aug.
More news about: Citius Oncology, Inc.
Aug 05, 2026, 06:00 ET Operation Homefront® Welcomes New Vice President of Field Development
She has also held fundraising leadership positions with the Crohn's & Colitis Foundation and Blood Cancers United (formerly The Leukemia & Lymphoma Society), consistently surpassing revenue goals while strengthening volunteer engagement and community impact.Known for her collaborative leadership
More news about: Operation Homefront
Aug 04, 2026, 09:48 ET Ochsner ranked No.1 in Louisiana by U.S. News & World Report
attackHeart bypass surgeryHeart failureHip fractureHip replacementKnee replacementLeukemia, lymphoma and myelomaLung cancer surgeryPacemaker implantationPneumoniaProstate cancer surgeryStrokeTranscatheter
More news about: Ochsner Health
Aug 04, 2026, 06:00 ET Grady Recognized as U.S. News & World Report High Performing Hospital
rankings. Grady earned top marks for care in Chronic Obstructive Pulmonary Disease (COPD), Heart Arrhythmia, Heart Failure, Kidney Failure, Leukemia, Lymphoma, and Myeloma, and Stroke. This is the highest distinction a hospital can earn as part of U.S. News' Best Hospitals Procedures & Conditions ratings.
More news about: Grady Health System
Aug 04, 2026, 05:00 ET MemorialCare Hospitals Recognized by U.S. News & World Report's 2026-2027 Best Hospitals in 38 High-Performing Rankings, One National in OB GYN
Leukemia, Lymphoma & Myeloma, Pacemaker Implantation and Pneumonia.Saddleback Medical Center earned High Performing ratings in 10 adult procedures and conditions: Abdominal Aortic Aneurysm Repair, Back Surgery (Spinal Fusion), Heart Arrhythmia, Heart Attack, Heart Failure, Leukemia, Lymphoma &
More news about: MemorialCare
Aug 02, 2026, 10:01 ET New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
[4]. Lymphoma Australia. Types of Lymphoma: Follicular Lymphoma. [Accessed July 2026].
More news about: Specialised Therapeutics
Jul 31, 2026, 07:47 ET AbbVie Reports Second-Quarter 2026 Financial Results
(epcoritamab) in combination with lenalidomide and rituximab (R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 EPCORE FL-1 trial, in which fixed-duration Tepkinly plus R2 achieved statistically
More news about: AbbVie
Jul 30, 2026, 14:30 ET Beat AML® Study Provides New Data on 14-Day vs. 28-Day Venetoclax-Azacitidine Treatment in AML
United® and the Beat AML® Master Clinical TrialBlood Cancer United (formerly The Leukemia & Lymphoma Society) is the largest global nonprofit focused on blood cancer patient support, research, and advocacy. The organization's mission is to cure blood
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society
Jul 30, 2026, 08:00 ET Curis Doses First Five Patients in TakeAim CLL Study
inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of
More news about: Curis, Inc.
Jul 30, 2026, 05:09 ET NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC
first‑line treatment for locally advanced or metastatic NSCLC who have PD-L1 tumor proportion score (TPS)≥1% and are EGFR-negative and anaplastic lymphoma kinase (ALK)-negative; and 2) sac‑TMT as first‑line treatment for patients with recurrent or metastatic TNBC who have a PD‑L1 CPS <10 or have recurred
More news about: Kelun-Biotech
Jul 29, 2026, 09:30 ET The Harry T. Mangurian, Jr. Foundation Surpasses $25 Million in Support of Blood Cancer United With New $4 Million Commitment
WASHINGTON, July 29, 2026 /PRNewswire/ -- Blood Cancer United® (formerly The Leukemia & Lymphoma Society) today announced a new $4 million commitment from The Harry T. Mangurian, Jr. Foundation, bringing the foundation's total support to more
More news about: BLOOD CANCER UNITED, INC.
Jul 29, 2026, 03:00 ET AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
recommended that patients be brought up to date with all immunizations, including prophylactic zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.MalignancyLymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised active-controlled study of
More news about: AbbVie
Jul 29, 2026, 03:00 ET AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
including prophylactic zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.MalignancyLymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised active-controlled study of
More news about: AbbVie